Olsen Anne Helene, Njor Sisse H, Lynge Elsebeth
Department of Epidemiology, University of Copenhagen, Copenhagen, Denmark.
Epidemiology. 2007 Jul;18(4):487-92. doi: 10.1097/EDE.0b013e318060cbbd.
Mammography screening is justifiable only if it leads to reduction in breast cancer mortality. However, evaluation of routine screening is not straightforward, as no unscreened control group is available. We report here on a cohort study of the effect of routine mammography on breast cancer mortality, and illustrate how variations in the analytic approach can affect the conclusions.
We used data from the mammography screening program in Copenhagen, Denmark, for the period 1991-2001. We used local historical, concurrent regional, and historical regional control groups, and included only deaths from breast cancers diagnosed during the observation periods. We examined the impact of various control groups, of including all breast cancer deaths, and of using individual data versus routine statistics.
Combining all 3 control groups gave an estimated 25% reduction in breast cancer mortality. The estimate was 20% using only a local historical control group, and 9% using only a concurrent regional control group. Including all breast cancer deaths resulted in an estimate of 21% reduction in breast cancer mortality. Using routine statistics and a concurrent regional control group resulted in an estimated increase of 6% in breast cancer mortality.
Estimated changes in breast cancer mortality following the introduction of routine mammography ranged from a 25% reduction (based on the best methodology) to a 6% increase with a less rigid study design. The estimated effect of routine mammography on breast cancer mortality is thus highly dependent on study design.
只有在能降低乳腺癌死亡率的情况下,乳腺钼靶筛查才是合理的。然而,对常规筛查进行评估并非易事,因为没有未接受筛查的对照组。我们在此报告一项关于常规乳腺钼靶筛查对乳腺癌死亡率影响的队列研究,并说明分析方法的差异如何影响研究结论。
我们使用了丹麦哥本哈根1991年至2001年期间乳腺钼靶筛查项目的数据。我们使用了当地历史对照组、同期区域对照组和历史区域对照组,且仅纳入观察期内诊断出的乳腺癌死亡病例。我们研究了不同对照组、纳入所有乳腺癌死亡病例以及使用个体数据与常规统计数据的影响。
综合所有3个对照组,估计乳腺癌死亡率降低了25%。仅使用当地历史对照组时估计降低20%,仅使用同期区域对照组时估计降低9%。纳入所有乳腺癌死亡病例后,估计乳腺癌死亡率降低21%。使用常规统计数据和同期区域对照组时,估计乳腺癌死亡率增加了6%。
引入常规乳腺钼靶筛查后,估计的乳腺癌死亡率变化范围从降低25%(基于最佳方法)到采用较宽松研究设计时增加6%。因此,常规乳腺钼靶筛查对乳腺癌死亡率的估计效果高度依赖于研究设计。